STRM.BIO

📍 Boston, United States🗓 Founded 2019👥 22 employees💰 Last funded 2023
Biotechnology Research🌐 strm.bio
Website LinkedIn
Based in Boston, MA, STRM.BIO (“storm bio”) is a pre-clinical, VC-backed biotechnology company that aims to fulfill the promise of gene therapy by leveraging extracellular vesicles (EVs) to deliver treatment directly to the patient (in vivo). Unlike viruses, EVs are natural carriers of nucleic acids and proteins with innate targeting capabilities, amenability to large scale/commercial manufacture, and low immunogenicity – which make them excellent cell messengers for gene therapies. Our proprietary EV platform is establishing a whole new class of therapeutics, yielding new therapies and making existing ones more effective. At STRM.BIO, we believe that our work has the potential to democratize gene therapy and bring hope for patients fighting rare diseases worldwide. We are currently recruiting team members who can help us make our vision a life-saving reality.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2019
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in STRM.BIO?
STRM.BIO has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did STRM.BIO last raise funding?
The most recent investment in STRM.BIO recorded on gritt.io was in 2023.
When was STRM.BIO founded?
STRM.BIO was founded in 2019.
What industry is STRM.BIO in?
STRM.BIO operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is STRM.BIO based?
STRM.BIO is headquartered in Boston, United States.